What Peptides Improve Mitochondrial Function?

← Back to Clinical Articles

Article: What Peptides Improve Mitochondrial Function?  |  Category: Peptide Therapy  |  Authored by: Brian Lamkin, DO

Why Mitochondrial Function Is the Central Aging Variable

Mitochondria produce approximately 90 percent of the ATP that powers every cellular process in the body. Muscle contraction, neuronal firing, immune cell activation, hormone synthesis, DNA repair, and tissue regeneration all require ATP^[1]. When mitochondrial function declines, every energy-dependent process deteriorates simultaneously. This is why mitochondrial dysfunction does not produce a single symptom. It produces the entire aging phenotype: progressive fatigue, declining exercise capacity, cognitive slowing, reduced immune surveillance, impaired recovery, and loss of tissue repair capacity. Conventional medicine does not measure or treat mitochondrial function. Functional and longevity medicine recognizes it as one of the most consequential and most targetable aging mechanisms.

How Mitochondria Decline with Age

Mitochondrial aging involves several concurrent processes. Mitochondrial DNA accumulates mutations at a higher rate than nuclear DNA because it lacks histones (protective packaging proteins) and has limited DNA repair mechanisms. The electron transport chain (ETC) complexes become less efficient, producing less ATP per unit of substrate while generating more reactive oxygen species (ROS) as a byproduct. NAD+ (nicotinamide adenine dinucleotide), the coenzyme essential for ETC function and sirtuin-mediated repair, declines approximately 50 percent between ages 40 and 60. Cardiolipin, the inner membrane phospholipid that organizes ETC complexes into efficient supercomplexes, deteriorates in content and composition. Mitophagy (the selective autophagy of damaged mitochondria) becomes less efficient, allowing dysfunctional mitochondria to persist and produce ROS without adequate ATP. And mitochondrial biogenesis (the production of new mitochondria through PGC-1alpha activation) declines as AMPK signaling weakens with age and insulin resistance.

MOTS-c: The AMPK Activating Mitochondrial Peptide

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA^[2]. Unlike most mitochondrial gene products which stay inside the mitochondria, MOTS-c is translocated to the nucleus and to the systemic circulation, functioning as a retrograde signaling molecule from mitochondria to the cell and to distant tissues. The primary mechanism: MOTS-c activates AMPK (AMP-activated protein kinase) by increasing the cellular AMP:ATP ratio. AMPK is the master regulator of cellular energy homeostasis and activates mitochondrial biogenesis through PGC-1alpha, enhances fatty acid oxidation (shifting metabolism toward fat utilization), improves skeletal muscle glucose uptake (independent of insulin signaling), activates autophagy and mitophagy (clearing damaged cellular components), and suppresses mTOR (shifting cellular priority from growth toward repair and maintenance). MOTS-c has been shown to improve exercise capacity, insulin sensitivity, and resistance to metabolic stress in aging models. It is sometimes described as an "exercise mimetic" because AMPK activation is one of the primary cellular responses to exercise, and MOTS-c activates many of the same downstream pathways. MOTS-c levels decline with age, correlating with declining metabolic health and exercise capacity.

MOTS-c Clinical Protocol

Administration: subcutaneous injection, typically 5mg administered 3 to 5 times per week. Cycles: 8 to 12 weeks on, followed by a washout period of 4 to 8 weeks. Timing: morning or pre-exercise (to complement the AMPK activation produced by physical activity). Monitoring: fasting insulin and HOMA-IR at baseline and 8 weeks (expect improvement as MOTS-c improves insulin sensitivity). Body composition assessment at baseline and end of cycle. Exercise capacity testing (VO2 max, time trials, or functional fitness assessments) to document objective improvement. Clinical response: patients typically report improved energy, better exercise endurance, faster recovery, and improved body composition (reduction in visceral fat, improved lean mass) within 4 to 8 weeks. MOTS-c is particularly valuable for patients with documented insulin resistance who need metabolic support alongside dietary and exercise interventions, and for patients in longevity protocols targeting accelerated biological aging.

SS-31 (Elamipretide): Stabilizing the Inner Mitochondrial Membrane

SS-31 is a cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane at concentrations approximately 5,000-fold higher than the cytoplasm^[3]. Its mechanism is specific: SS-31 binds to cardiolipin, the signature phospholipid of the inner mitochondrial membrane. Cardiolipin organizes the electron transport chain complexes (I, III, IV) and ATP synthase into supercomplexes that enable efficient electron transfer and ATP production. With aging, cardiolipin is oxidized by ROS, loses its structural integrity, and the ETC supercomplexes disassemble. This produces less ATP, more electron leakage, more ROS, and a vicious cycle of mitochondrial decline. SS-31 stabilizes cardiolipin against oxidation, preserves supercomplex organization, restores electron transport efficiency, reduces ROS production, and improves ATP output from existing mitochondria. This complements MOTS-c: MOTS-c makes new mitochondria (biogenesis), while SS-31 improves the function of the mitochondria you already have.

SS-31 Clinical Applications and Evidence

SS-31 (elamipretide) is currently in clinical trials for several conditions with a mitochondrial component: Barth syndrome (a genetic cardiolipin deficiency), primary mitochondrial myopathy, age-related macular degeneration (retinal cells are extremely mitochondria-dependent), heart failure with preserved ejection fraction (HFpEF), and age-related skeletal muscle decline. Published data demonstrates improvement in exercise tolerance, cardiac function, and mitochondrial biomarkers in these conditions. In longevity practice, SS-31 is used for patients with documented mitochondrial-driven fatigue, declining exercise capacity that does not respond to conventional interventions, and as part of comprehensive anti-aging protocols targeting the mitochondrial hallmark of aging. Administration: subcutaneous injection. Dosing protocols vary (clinical trials have used 4mg to 40mg depending on the condition). In longevity applications, lower doses are typically used in 8 to 12 week cycles.

Humanin: Cytoprotection Against Mitochondrial Stress

Humanin is a 24-amino-acid peptide encoded by the 16S ribosomal RNA gene of mitochondrial DNA^[4]. It was originally discovered in a screen for factors that protect neurons against amyloid-beta toxicity in Alzheimer's disease. Humanin has since been shown to protect cells against a broad range of stressors: oxidative stress, endoplasmic reticulum stress, serum deprivation, and apoptotic signaling. Its mechanisms include activation of the STAT3 signaling pathway (promoting cell survival), reduction of ROS production, inhibition of pro-apoptotic BAX translocation to mitochondria, and enhancement of cellular stress resistance. Humanin levels decline with age and are lower in patients with Alzheimer's disease, cardiovascular disease, and diabetes. In animal models, humanin analogs have demonstrated neuroprotection, cardioprotection, improved insulin sensitivity, and extended lifespan. Clinical applications in humans are in early stages, with humanin positioned as a cytoprotective peptide for neuroprotection, cardioprotection, and cellular resilience enhancement in aging patients.

The Complementary Mitochondrial Support Stack

Mitochondrial peptides work most effectively when combined with foundational mitochondrial support interventions. NAD+ precursors (NMN 500 to 1000mg daily or nicotinamide riboside): NAD+ is the coenzyme required for Complex I of the electron transport chain and for sirtuin activation (sirtuins regulate mitochondrial biogenesis and DNA repair). NAD+ declines 50 percent between ages 40 and 60, and repletion is one of the most impactful mitochondrial interventions. CoQ10 (200 to 400mg as ubiquinol): CoQ10 is the electron carrier between Complexes I/II and Complex III. It is depleted by statin medications and declines with age. Ubiquinol (the reduced, bioavailable form) is preferred over ubiquinone. Alpha-lipoic acid (300 to 600mg): a mitochondrial antioxidant that also recycles glutathione and CoQ10. PQQ (pyrroloquinoline quinone, 10 to 20mg): promotes mitochondrial biogenesis through a different pathway than AMPK. Exercise: resistance training and high-intensity interval training are the most potent non-pharmacological stimuli for mitochondrial biogenesis, AMPK activation, and PGC-1alpha expression. No supplement or peptide replaces the mitochondrial benefits of consistent exercise.

When to Consider Mitochondrial Peptides

Mitochondrial peptide therapy is appropriate when foundational mitochondrial support (NAD+, CoQ10, exercise, sleep optimization) has been implemented and the patient demonstrates persistent fatigue not explained by thyroid, hormonal, or metabolic causes (after Free T3, DHEA-S, and fasting insulin have been optimized), declining exercise capacity or recovery despite adequate training and nutrition, documented metabolic decline (rising fasting insulin, declining body composition) that has not fully responded to lifestyle and metabolic interventions, or a comprehensive longevity protocol targeting the mitochondrial hallmark of accelerated aging. Mitochondrial peptides should not be prescribed as a first-line intervention for fatigue without evaluating and addressing the more common and treatable causes: thyroid dysfunction, iron deficiency, cortisol dysregulation, sleep disorders, and undiagnosed metabolic conditions.

Monitoring Mitochondrial Peptide Therapy

Objective monitoring for mitochondrial peptide protocols: fasting insulin and HOMA-IR at baseline and 8 to 12 weeks (MOTS-c should improve insulin sensitivity). Body composition (DEXA) at baseline and 3 to 6 months. Exercise capacity assessment (VO2 max, timed functional tests, grip strength) at baseline and end of cycle. hs-CRP (mitochondrial dysfunction drives inflammation through ROS and DAMP release; improving mitochondrial function should reduce inflammatory burden). Organic acid testing (urinary markers of mitochondrial metabolic function) when available. Subjective tracking: energy levels, exercise endurance, recovery time, cognitive clarity, and sleep quality. The goal is documenting measurable improvement in specific biomarkers and functional endpoints, not subjective "feeling better" without confirmatory data.

The Lamkin Clinic Approach

Mitochondrial peptide therapy at The Lamkin Clinic is prescribed within a comprehensive mitochondrial assessment. The evaluation includes metabolic markers (fasting insulin, HOMA-IR, HbA1c), hormonal assessment (Free T3, DHEA-S, IGF-1, cortisol), inflammatory markers (hs-CRP), body composition analysis, and exercise capacity assessment. Foundational interventions (NAD+ precursors, CoQ10, exercise programming, sleep optimization) are initiated first. Mitochondrial peptides are added when the foundation is in place and objective evidence of mitochondrial-specific decline persists. MOTS-c is the most commonly prescribed mitochondrial peptide for metabolic and exercise applications. SS-31 is added for patients with documented mitochondrial membrane dysfunction or persistent fatigue despite MOTS-c and foundational support. Monitoring confirms response at defined intervals and guides protocol adjustment.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Kim SJ, et al. Mitochondrial-derived peptides in aging and age-related diseases. J Gerontol A Biol Sci Med Sci. 2018;73(12):1571-1579.
2. [2]Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
3. [3]Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
4. [4]Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci USA. 2001;98(11):6336-6341.